On Thursday, the Food and Drug Administration approved the first generic version of the EpiPen, used to treat severe allergic reactions to everything from food to insect bites.
Teva Pharmaceuticals is now authorized to sell the generic versions of EpiPen and Epi Pen Jr., made by Mylan. "This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential shortages," FDA Commissioner Scott Gottlieb said in a statement.
EpiPen is the most widely prescribed epinephrine auto-injector in the U.S. Mylan has come under fire for charging as much as $600 for a package of two pens. Teva has not said how much its generic version will cost. Catherine Garcia
Researchers at the Mayo Clinic have discovered five genetic mutations linked to a high risk of triple-negative breast cancer, and the finding should help doctors treat the aggressive form of cancer.
Their study was published Monday in the Journal of the National Cancer Institute. The researchers looked at the genetic panels of nearly 11,000 patients who had been diagnosed with the form of cancer, and they found five genetic mutations — BARD1, BRCA1, BRCA2, PALB2, and RAD51D — that were associated with triple-negative breast cancer. The course of treatment for this type of cancer is typically extensive chemotherapy, and it still has a lower five-year survival rate than other kinds of breast cancer, the researchers said.
Dr. Fergus Couch, a Mayo Clinic geneticist and the study's lead author, told NBC News this study "is the first to establish which genes are associated with high lifetime risks of triple-negative breast cancer." Doctors will now be able to screen patients diagnosed with triple-negative breast cancer for these genes, and if the mutations are found, they would be closely monitored in case of a recurrence. More than 30 percent of patients in the study did not have a family history of breast cancer, and "unless we start testing everyone for these genes, it's unclear how we can effectively screen for first-time cases," Dr. Sandra Swain from Georgetown University Medical Center told NBC News. Catherine Garcia
The Centers for Disease Control and Prevention on Friday reported the fourth human case of an antibiotic-resistant superbug. The latest case was found in a 2-year-old in Connecticut, who may have contracted the superbug during a trip to the Caribbean in June. The child had a strain of E. coli that contained the gene mcr-1, which scientists have found to be resistant to the antibioitic colistin, which is the treatment administered as a last resort when patients aren't responding to other antibiotics.
Luckily, the girl's case proved treatable with drugs other than colistin, and health experts do not believe the germs were passed along to anyone else. Still, the case is alarming for health experts who have been carefully tracking the gene; if the gene spreads to other bacteria, scientists believe that it could eventually morph into a superbug invincible to all known antibiotics. Becca Stanek